CJC-1295 No DAC

CJC-1295 was developed by ConjuChem Biotechnologies in the early 2000s as part of efforts to create GHRH analogs with improved pharmacokinetic properties. The original CJC-1295 with DAC (drug affinity complex) was designed for prolonged activity through covalent binding to circulating albumin, a pharmacokinetic strategy characterized in the published literature before development of that version was discontinued. The No DAC variant retains the same GRF(1-29) substitutions without the albumin-binding complex. Published work under the CJC-1295 name — including Teichman et al. (2006), Alba et al. (2006) and Ionescu & Frohman (2006) — was generated with the DAC-bearing molecule. Those findings are mentioned here only as naming history; they do not characterise the no-DAC material supplied on this page.

Jetté L. et al. (2005).

CAS #: 863288-34-0
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3367.9 g/mol
PubChem ID: 91976842

Published research applicable to this material concerns the GRF(1-29) analog series rather than the DAC-bearing compound: resistance to dipeptidyl peptidase-IV cleavage, the contribution of individual amino-acid substitutions to receptor binding and stability, and growth hormone release in cultured pituitary cells and animal models. Literature specific to the no-DAC analog under the CJC-1295 name is limited.

Key Areas of Research:

• Stability: DPP-IV resistance, position-2 substitution
• Pharmacology: Target binding, somatotroph, cAMP
• Downstream: Hepatic signaling, cascades, activation
• Endocrine: IGF-1 pathway, lipolytic signaling, protein-synthesis pathways

Together, this work makes the tetrasubstituted GRF(1-29) analog a defined, enzymatically stabilised material for examining GHRH receptor activation and hypothalamic-pituitary-somatotroph signaling. Duration-of-action figures reported for the DAC-bearing compound do not apply to it.

Campbell R.M. et al., Peptides, 1994

Bongers J. et al., Biochimica et Biophysica Acta, 1992

Campbell R.M. et al. (1994). Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides, 15(3):489–95. PubMed ID 7937325.

Bongers J. et al. (1992). Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta, 1122(2):147–53. PubMed ID 1353684.

Jetté L. et al. (2005). Endocrinology, 146(7):3052–8. PubMed ID 15817669. Cited as naming background: this study characterised the DAC-bearing CJC-1295, not the no-DAC material supplied here.